American Society of Hirudotherapy

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran

Research article published in Scientific reports (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportSalivary PharmacologyKim JM et al. · Scientific reports, 2025

Abstract

Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than previously assumed. Idarucizumab, a monoclonal antibody fragment, binds to both free and thrombin-bound dabigatran, neutralizing its anticoagulant effects. However, its efficacy in reversing anticoagulation induced by dabigatran acylglucuronide remains unclear. This study aimed to evaluate whether idarucizumab differentially reverses the anticoagulant effects of dabigatran and dabigatran acylglucuronide. In vitro experiments were conducted using blood from healthy, drug-free donors. Plasma samples were spiked with either dabigatran or dabigatran acylglucuronide, followed by idarucizumab. Standard coagulation assays, including prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), as well as thrombin generation assays (TGA), were performed. At a concentration of 1 µM, idarucizumab demonstrated significantly greater reversal of dabigatran acylglucuronide-induced anticoagulation than that of dabigatran in PT, aPTT, and TT assays. Consistently, TGA showed stronger neutralization of dabigatran acylglucuronide, with IC50 values for Cmax, endogenous thrombin potential, and lag time at least 2.0-fold higher than those of dabigatran. These findings indicate that idarucizumab exerts a more potent reversal effect on dabigatran acylglucuronide compared to dabigatran.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsDabigatranAntibodies, Monoclonal, HumanizedHumansBlood CoagulationAnticoagulantsAntithrombinsBlood Coagulation TestsThrombin TimePartial Thromboplastin TimeThrombinProthrombin Time

Summary

Using drug-free donor plasma spiked with either compound, in vitro assays showed idarucizumab reversed dabigatran acylglucuronide-induced anticoagulation more potently than dabigatran's, with thrombin-generation IC50 values at least 2.0-fold higher.

Context

This in vitro study evaluated whether idarucizumab differentially reverses the anticoagulant effects of dabigatran versus dabigatran acylglucuronide (an active metabolite), spiking plasma from healthy donors with each compound followed by idarucizumab. It found that idarucizumab demonstrated significantly greater reversal of dabigatran acylglucuronide-induced anticoagulation than dabigatran across PT, aPTT, thrombin time, and thrombin generation assays, with IC50 values for acylglucuronide reversal at least 2.0-fold higher than those for dabigatran. The abstract contains no mention of leeches, hirudotherapy, hirudin, or any leech-derived compounds. This is a purely in vitro study using spiked plasma samples with no clinical or animal data.

Citation

Reference (Vancouver style)

Kim JM, Bang YY, Kim KA, Park JW, Park JY. Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran. Sci Rep. 2025;15(1):21967. doi:10.1038/s41598-025-08417-0. PMID: 40595373

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.